Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Temferon |
Synonyms | |
Therapy Description |
Temferon comprises autologous hematopoietic stem progenitor cells engineered with a lentiviral vector to express IFN-alpha2 in the tumor microenvironment, which may induce apoptosis in tumor cells and activate antitumor immune response (Blood (2021) 138 (Supplement 1): 2844, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Temferon | Autologous CD34+-enriched HSPCs transduced with VSV-G encoding IFN-a2 | Temferon comprises autologous hematopoietic stem progenitor cells engineered with a lentiviral vector to express IFN-alpha2 in the tumor microenvironment, which may induce apoptosis in tumor cells and activate antitumor immune response (Blood (2021) 138 (Supplement 1): 2844, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03866109 | Phase Ib/II | Temferon | A Study Evaluating Temferon in Patients with Glioblastoma & Unmethylated MGMT (TEM-GBM) | Recruiting | ITA | 0 |